I get your frustration on one hand, however - I like the idea that ARNA and Lief want to focus on the capabilities of BELVIQ without bashing the competition. To put it into some contexr, I have participated in a number of vendor solution assessments around big ticket IT purchases. Nothing frosts me more than having a vendor spend more time trashing the competition than touting the attributes of his/her own product.
ARNA has every asset it needs to make a huge inroad in the obesity/diabetes market - much better to stand on its own merits than even mention the competition (why give VVUS air time??).